Economic Evidence on Cost Sharing and Alternative Insurance Designs to Address Moral and Behavioral Hazards in High-Income Health Care Systems: A Systematic Review [0.03%]
高收入国家医疗体系中道德和行为风险的经济证据：关于费用分担和替代保险设计的一篇综述性文章
Marlon Graf,James R Baumgardner,Ulrich Neumann et al.
Marlon Graf et al.
In health insurance, "moral hazard" describes the concept that coverage without an out-of-pocket cost to consumers could result in health care utilization beyond economically efficient levels. In response, payers in the United States (US) h...
Developer and Partnership Differences in COVID-19 and Other Infections: Insights from DNA Vaccines [0.03%]
新冠肺炎及其他感染下的研发与合作关系差异：基因疫苗的启示
Ryo Okuyama
Ryo Okuyama
Historically, vaccine development has been heavily supported by government and public institutions. On the other hand, private biopharmaceutical companies have played a significant role in the development of innovative new therapies using n...
Technology Assessment vs. Technology Appraisal-How to Strengthen the Science/Value Dichotomy with EU HTA? [0.03%]
技术评估与技术评价：如何利用欧盟卫生技术评估强化科学/价值二分法？
Sandro Gsteiger,Heiner C Bucher,James Ryan et al.
Sandro Gsteiger et al.
Many countries around the world use health technology assessment (HTA) to inform reimbursement and pricing decisions. HTA is often split into two steps, called assessment and appraisal. While the term HTA itself has been defined by internat...
Adapting Efficiency Analysis in Health Systems: A Scoping Review of Data Envelopment Analysis Applications During the COVID-19 Pandemic [0.03%]
基于数据包络分析的卫生系统效率适应性研究——新冠肺炎疫情应对期间的应用述评
Athanasios Mitakos,Panagiotis Mpogiatzidis
Athanasios Mitakos
Objective: To synthesize the current evidence base concerning the application of Data Envelopment Analysis (DEA) in healthcare efficiency during the COVID-19 pandemic using a scoping review of 13 primary studies. Methods: We consulted datab...
INEAS's Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia [0.03%]
一项关于维莫非尼的成本效益分析：为突尼斯开启基于价值的定价之路
Mouna Jameleddine,Nabil Harzallah,Hela Grati et al.
Mouna Jameleddine et al.
The Tunisian Health Technology Assessment (HTA) body, INEAS, conducted a cost-effectiveness analysis (CEA) of vemurafenib in the treatment of locally advanced or metastatic BRAF V600-mutated melanoma. The objective of this analysis was to e...
A Causal Inference Approach to Mediation Analysis in Vitreomacular Traction: How Much Does Traction Resolution Mediate Functional Outcomes? [0.03%]
玻璃膜剥脱对黄斑视网膜牵引症预后的影响有多大？因果推理方法在视网膜牵引性疾病中介效应分析中的应用
Benedicte Lescrauwaet,Stijn Vansteelandt,Timothy L Jackson et al.
Benedicte Lescrauwaet et al.
Modern mediation analysis techniques supplement the primary intention-to-treat analysis with the aim to shed light onto the treatment mechanism. We investigate to what extent the anatomic marker vitreomacular adhesion resolution (VMAR) medi...
Non-Medical Switching or Discontinuation Patterns among Patients with Non-Valvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States: A Claims-Based Analysis [0.03%]
美国非瓣膜性房颤患者使用直接口服抗凝药的非医学换药或停药模式：基于理赔数据的分析
Michael Ingham,Hela Romdhani,Aarti Patel et al.
Michael Ingham et al.
This study assessed direct-acting oral anticoagulant (DOAC) switching/discontinuation patterns in patients with non-valvular atrial fibrillation (NVAF) in 2019, by quarter (Q1-Q4), and associated socioeconomic risk factors. Adults with NVAF...
The Knowledge and Application of Economics in Healthcare in a High-Income Country Today: The Case of Belgium [0.03%]
当今高收入国家医疗保健中的经济学知识和应用——以比利时为例
Baudouin Standaert,Désirée Vandenberghe,Mark P Connolly et al.
Baudouin Standaert et al.
Healthcare is a huge business sector in many countries, focusing on the social function of delivering quality health when people develop illness. The system is essentially financed by public funds based on the solidarity principle. With a l...
Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands [0.03%]
荷兰细胞和基因疗法的市场准入挑战及解决方案
Rimma Velikanova,Sharon Wolters,Hinko S Hofstra et al.
Rimma Velikanova et al.
With the increasing pipeline of cell and gene therapies (CGTs) and the expected surge in the number of approvals, understanding the market access landscape becomes crucial for timely patient access. This study evaluates the challenges Dutch...
Mark Nuijten,Stefano Capri
Mark Nuijten
Background: The purpose of this paper is to address how to handle uncertainty when performing an economic valuation of a medical innovation R&D project in orphan diseases from the perspective of the investor. Methods: We describe the specif...